Objective Atopic dermatitis (AD), a chronic inflammatory skin disease characterised by itchy skin lesions and rashes, affects 1 child in 5-10, and 3% of adults. Without effective treatment it can have a severe negative impact on quality of life. Treatment has historically been dominated by topical steroid creams, although consumers – reticent to using steroids over long periods, and for convenience (some steroid treatments are prescription only) – are increasingly opting for non-pharma products with natural attributes. These natural products, however, tend to have high toxicity and therefore to create unpleasant side effects. Glycomar’s eczema treatment, Fucoderm, directly addresses these shortcomings and responds to consumer preferences. Using an active pharmaceutical ingredient extracted from brown seaweed – a Fucoidan – Glycomar has created a novel topical formulation for maintenance treatment. The product is the first commercial application of Glycomar’s extensive glycobiology expertise – the team has over 100 years’ collective experience in marine biotechnology and drug discovery/development – and it will be targeted towards mild- to moderate AD sufferers. Together these cases comprise 80-90% of the €4b market, which is growing at 3,8% – maximising potential impact. The company, which has been working for 10 years in pursuit of novel immunomodulatory saccharides, has a track record of attracting non-dilutive grant funding, and of creating cash generative, value enhancing partnerships. Successful commercialisation of Fucoderm would enable Glycomar to meet its target of reaching profitability by 2019, in turn facilitating the launch of other consumer healthcare, nutraceutical and cosmetic products in the development pipeline. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinedermatology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator GLYCOMAR LIMITED Net EU contribution € 50 000,00 Address DUNSTAFFNAGE MARINE LABOARATORY EUROPEAN CENTRE FOR MARINE BIOTECHNOLOGY DUNBEG ARGYLL PA37 1QA OBAN United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Scotland Highlands and Islands Lochaber, Skye & Lochalsh, Arran & Cumbrae and Argyll & Bute Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
